MDR and
tumor migration and invasion are still the main obstacles to effective
breast cancer chemotherapies.
Transgelin 2 has recently been shown to induce drug resistance,
tumor migration, and invasion. The aim of this study was to determine the biological functions of
Transgelin 2 and the mechanism underlying how
Transgelin 2 induces
paclitaxel (PTX) resistance and the migration and invasion of
breast cancer. We detected that the
protein level of
Transgelin 2 was significantly upregulated in
breast cancer tissues compared with adjacent nontumor tissues. A bioinformatics analysis indicated that
Transgelin 2 was significantly related to clinicopathologic parameters and patient prognosis. Overexpression of
Transgelin 2 enhanced the migration and invasion of human
breast cancer cells and decreased the sensitivity of
breast cancer cells to
paclitaxel. Meanwhile, the
tumorigenesis and
metastasis of
breast cancer cells were also enhanced by
Transgelin 2 overexpression in vivo Moreover,
Transgelin 2 overexpression activated the PI3K/Akt/GSK-3β pathway by increasing the phosphorylation levels of Akt and GSK-3β and decreasing the expression of PTEN. We also found that
Transgelin 2 could directly interact with PTEN and was located upstream of PTEN. Furthermore, the PI3K/Akt pathway inhibitor
MK-2206 reversed the resistance to
paclitaxel and inhibited the migration and invasion of
breast cancer cells. These findings indicate that
Transgelin 2 promotes
paclitaxel resistance and the migration and invasion of
breast cancer by directly interacting with PTEN and activating the PI3K/Akt/GSK-3β pathway.
Transgelin 2 may therefore be useful as a novel
biomarker and therapeutic target for
breast cancer.